After China probe, is AstraZeneca's new US$2.5 billion plan a blueprint for foreign firms? | South China Morning Post

Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China-based research – plus the company’s first v
Read more...